Zobrazeno 1 - 10
of 214
pro vyhledávání: '"TOSHIYUKI HARADA"'
Autor:
Kana Hashimoto, MD, Daisuke Morinaga, MD, Hajime Asahina, MD, PhD, Mina Ishidoya, MD, Hajime Kikuchi, MD, PhD, Hiroshi Yokouchi, MD, PhD, Toshiyuki Harada, MD, PhD, Osamu Honjo, MD, Ryota Shigaki, MD, Taichi Takashina, MD, PhD, Yuka Fujita, MD, PhD, Mamoru Takahashi, MD, PhD, Yasutaka Kawai, MD, Ryotaro Kida, MD, Kenichiro Ito, MD, Noriaki Sukoh, MD, PhD, Ayumu Takahashi, MD, PhD, Fumihiro Hommura, MD, PhD, Yoshihito Ohhara, MD, PhD, Megumi Furuta, MD, PhD, Satoshi Konno, MD, PhD, Yukio Hosomi, MD, PhD, Satoshi Oizumi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100715- (2024)
Introduction: Oligometastasis and oligoprogression (OP) has not been adequately defined in extensive-stage SCLC (ES-SCLC) and may be a good indication for adding local treatment. Therefore, this multicenter study aimed to investigate the prognostic i
Externí odkaz:
https://doaj.org/article/6a9e9af6ebb84315b50bcf56a349d75d
Autor:
Yosuke Kawashima, Osamu Ishimoto, Eisaku Miyauchi, Tomohiro Sakakibara, Toshiyuki Harada, Kazuhiro Usui, Akira Inoue, Shunichi Sugawara
Publikováno v:
Thoracic Cancer, Vol 14, Iss 27, Pp 2804-2810 (2023)
Abstract Background This phase II trial was designed to evaluate the efficacy and safety of S‐1 combined with weekly irinotecan as a second‐ or third‐line treatment for patients with advanced or recurrent squamous cell lung cancer. Methods Pati
Externí odkaz:
https://doaj.org/article/7762f015da734d1f801fd33d7a6edbc5
Autor:
Daisuke Morinaga, Hajime Asahina, Shotaro Ito, Osamu Honjo, Hisashi Tanaka, Ryoichi Honda, Hiroshi Yokouchi, Keiichi Nakamura, Kei Takamura, Fumihiro Hommura, Yasutaka Kawai, Kenichiro Ito, Noriaki Sukoh, Keiki Yokoo, Ryo Morita, Toshiyuki Harada, Taichi Takashina, Tomohiro Goda, Hirotoshi Dosaka‐Akita, Hiroshi Isobe, the Hokkaido Lung Cancer Clinical Study Group Trial
Publikováno v:
Cancer Medicine, Vol 12, Iss 10, Pp 11525-11541 (2023)
Abstract Purpose Immune‐checkpoint inhibitors (ICIs) are effective against advanced non‐small cell lung cancer (NSCLC). However, whether the efficacy and safety of ICI treatment in elderly patients are similar to those in younger patients is uncl
Externí odkaz:
https://doaj.org/article/e841a5a350844541b0287c7aee9ab30b
Autor:
Sae Akiyama, Chisa Murayama, Saori Aizawa, Arei Mizushima, Yukiko Maeda, Natsuko Taniguchi, Katsura Nagai, Toshiyuki Harada
Publikováno v:
Respirology Case Reports, Vol 11, Iss 9, Pp n/a-n/a (2023)
Abstract A 35‐year‐old woman experienced left back pain after a 2‐h flight. She reported coughing and left back pain 1 day later when she presented to our hospital. Chest computed tomography showed pneumothorax of the left lung, bronchiectasis,
Externí odkaz:
https://doaj.org/article/4a32e2a1636a44288b3211f747641423
Autor:
Eisaku Miyauchi, Hisashi Tanaka, Atsushi Nakamura, Toshiyuki Harada, Taku Nakagawa, Mami Morita, Daisuke Jingu, Tomoya Kuda, Shunichi Gamou, Ryota Saito, Akira Inoue
Publikováno v:
Thoracic Cancer, Vol 12, Iss 21, Pp 2886-2893 (2021)
Abstract Background NJLCG1402 was a phase I/II trial investigating biweekly nanoparticle albumin‐bound paclitaxel (nab‐PTX) in patients with advanced non‐small cell lung cancer (NSCLC). Methods The study included patients aged ≥20 years with
Externí odkaz:
https://doaj.org/article/1d2e818515ca48b8833458e79cf91807
Autor:
Gaku Yamamoto, Hajime Asahina, Osamu Honjo, Toshiyuki Sumi, Atsushi Nakamura, Kenichiro Ito, Hajime Kikuchi, Fumihiro Hommura, Ryoichi Honda, Keiki Yokoo, Yuka Fujita, Satoshi Oizumi, Ryo Morita, Yasuyuki Ikezawa, Hisashi Tanaka, Nozomu Kimura, Takaaki Sasaki, Noriaki Sukoh, Taichi Takashina, Toshiyuki Harada, Hirotoshi Dosaka-Akita, Hiroshi Isobe, the Hokkaido Lung Cancer Clinical Study Group Trial
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line th
Externí odkaz:
https://doaj.org/article/30fdf5599db64195b591b2c71f3f2250
Autor:
Hideki Terai, MD, Kenzo Soejima, MD, Asanao Shimokawa, PhD, Hidehito Horinouchi, MD, Junichi Shimizu, MD, Tetsunari Hase, MD, Ryota Kanemaru, MD, Kana Watanabe, MD, Kiichiro Ninomiya, MD, Naoko Aragane, MD, Noriko Yanagitani, MD, Yoshihiko Sakata, MD, Masahiro Seike, MD, Daichi Fujimoto, MD, Masashi Kasajima, MD, Akihito Kubo, MD, Sojiro Kusumoto, MD, Yoshitaka Oyamada, MD, Keiichi Fujiwara, MD, Masahide Mori, MD, Midori Hashimoto, MD, Masato Shingyoji, MD, Masahiro Kodani, MD, Jin Sakamoto, MD, Toshihiko Agatsuma, MD, Kosuke Kashiwabara, MD, Minehiko Inomata, MD, Motoko Tachihara, MD, Kazuhisa Tanaka, MD, Kenji Hayashihara, MD, Nobuyuki Koyama, MD, Kaoru Matsui, MD, Koichi Minato, MD, Daisuke Jingu, MD, Hiroyuki Sakashita, MD, Satoshi Hara, MD, Tomoyuki Naito, MD, Asuka Okada, MD, Masayuki Tanahashi, MD, Yuki Sato, MD, Koichiro Asano, MD, Takayuki Takeda, MD, Kensuke Nakazawa, MD, Toshiyuki Harada, MD, Kazuhiko Shibata, MD, Tatsuo Kato, MD, Etsuo Miyaoka, PhD, Ichiro Yoshino, MD, Akihiko Gemma, MD, Tetsuya Mitsudomi, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100404- (2022)
Introduction: Pembrolizumab is a programmed death-ligand 1 inhibitor that was initially indicated for monotherapy in patients with advanced lung cancer. The Japanese Lung Cancer Society conducted an observational study on pembrolizumab using confirma
Externí odkaz:
https://doaj.org/article/67a827674fcd4c4087dafceff77375be
Autor:
Koya Ito, Yukiko Maeda, Akane Mita, Saori Aizawa, Arei Mizushima, Natsuko Taniguchi, Katsura Nagai, Hiroki Shomura, Atsuo Hattori, Toshiyuki Harada
Publikováno v:
Respirology Case Reports, Vol 10, Iss 11, Pp n/a-n/a (2022)
Key message IgG4‐related lung disease (IgG4‐RLD) can present with various types of radiological findings such as nodule, ground‐glass opacity, alveolar interstitial, and bronchovascular involvement. IgG4‐RLD generally manifests as mild clinic
Externí odkaz:
https://doaj.org/article/30a8b026742e46c9a27bfd5455605909
Autor:
Hisashi Tanaka, Yukihiro Hasegawa, Yuka Fujita, Atsushi Nakamura, Eiki Kikuchi, Yasutaka Kawai, Toshiyuki Harada, Naomi Watanabe, Hiroshi Yokouchi, Kazuhiro Usui, Ryota Saito, Hiroshi Watanabe, Tomomi Masuda, Tatsuro Fukuhara, Keita Kudo, Ryoichi Honda, Satoshi Oizimi, Makoto Maemondo, Akira Inoue, Naoto Morikawa
Publikováno v:
Thoracic Cancer, Vol 12, Iss 14, Pp 2113-2121 (2021)
Abstract Background A cisplatin plus irinotecan (CPT‐11) regimen is used for patients with extensive disease small cell lung cancer (ED‐SCLC). Amrubicin (AMR) is primarily used for relapsed SCLC. The HOT1401/NJLCG1401 trial, an open‐label rando
Externí odkaz:
https://doaj.org/article/c0e9bc75e14647f5afcebfe007cf88f5
Autor:
Yukihiro Toi, Takao Kobayashi, Toshiyuki Harada, Taku Nakagawa, Yoshiaki Mori, Tomoya Kuda, Shunichi Sugawara
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundDiarrhea post-antibiotic use is primarily attributed to mucosal lesions induced by Clostridium (Clostridioides) difficile (C. difficile) infection (CDI). Cancer patients undergoing chemotherapy might have a higher risk of CDI even when prio
Externí odkaz:
https://doaj.org/article/5c601ce2fb1d4ab2aa934bf7c791d5b2